The changes proposed by HB1544 are significant as they amend existing provisions regarding the pricing and dispensing of custom compound medications. By requiring a preauthorization for prescriptions longer than seven days, the bill aims to prevent excessive or unnecessary healthcare costs that could burden the workers' compensation system. Furthermore, the proposal aims to ensure that reimbursement structures are aligned with actual costs as determined by manufacturers, potentially reducing instances of overcharging for prescription medications. The bill is intended to streamline the reimbursement process while maintaining quality care for compensated injuries.
Summary
House Bill 1544 is an amendment to the Workers' Compensation Act focusing on custom compound medications. It introduces specific conditions for the approval of payments related to these medications, emphasizing that charges should reflect the actual amount of each component drug and its National Drug Code number. Additionally, the legislation stipulates that a healthcare provider may only prescribe a one-time 7-day supply of medication unless a longer duration is preauthorized by the employer. This measure is designed to impose more stringent controls on the prescription and reimbursement of compound drugs under workers' compensation claims.
Contention
However, there are notable concerns regarding the implications of this bill. Some critics argue that the preauthorization requirement could delay necessary treatments for injured workers, as they would depend on their employers' approval for medications that might be crucial for recovery. Additionally, there could be worries raised about accessibility to necessary medications, particularly for those with ongoing medical needs. Proponents of the bill assert that the measures will promote fair pricing and accountability among providers and insurers, ultimately benefiting the system. However, the balance between cost control and patient care creates a potential point of contention among stakeholders.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.